J.B. Chemicals & Pharmaceuticals Ltd.

JBCHEPHARMNSE

Market snapshot · 2026-08-13 10:28 UTC

₹2,416.10

+₹7.20 (+0.30%)

MARKET CAP

₹38.79K Cr

STOCK P/E

54.2x

52W HIGH

₹2,525.50

52W LOW

₹1,638.50

BOOK VALUE

₹259.05

EPS

₹44.56

ROE

18.69%

SECTOR

Health Care

DEBT/EQUITY

0.09

VOLUME

47.79L

P/B RATIO

9.33x

PEG RATIO

-1.74

Sector

Health Care

Themes

Pharmaceuticals

Dividend

Earnings

AI Summary

✦ Clartha

Price Forecast

Current

₹2,416

High Target

₹2,744

▲ +13.6%

Median Target

₹2,327

▼ -3.7%

Low Target

₹1,900

▼ -21.4%

Price history (1Y)

Analyst target range

7 analysts

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange (₹)Probability

3M₹2,172 - ₹2,80380%

6M₹2,104 - ₹3,01880%

12M₹2,036 - ₹3,39180%

Realized vol: +19.9% · Drift: +10.4%

Revenue Forecast

₹ Cr

Mar '26Current₹836.0

Sep 2026 ETrend estimate range

High₹1,135.1Base₹1,051.0Low₹966.9

PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share

Mar '26Current₹6.01

Sep 2026 ETrend estimate range

High₹13.91Base₹12.42Low₹10.93

PastCurrentTrend estimate: Low / Base / High

Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook

Mixed

45%

Analyst Consensus

Unavailable

From 7 analysts

Mean upside-3.6%

Fundamentals

Moderate

Fundamentals institutional score is 57 using EVA spread proxy 6.7%; growth durability 13.1.

Valuation

Premium valuation

Valuation institutional score is 32 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Weakening

Analyst View institutional score is 28 using mean target upside -3.6%; dispersion penalty 14.5; recommendation breadth from available consensus.

Technical Structure

Mixed Momentum

Technicals institutional score is 61 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Unavailable

This data source has not been supplied for the decision payload.

Signal Summary

Market intelligence remains Mixed. Available evidence provides partial support, while valuation and analyst consensus remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals ModerateValuation Premium valuationAnalyst Consensus WeakeningTechnical Structure Mixed Momentum

Key Data Points

Mean Target Price2,328.1 target

Mean Upside-3.6%

Technical Score61%

Fundamental Score57%

Data CoverageHigh

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 40.8% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.94). Confidence: 87%.

Live forward EPS implies next-12-month EPS of ₹73.70. Applying the stock's normalized valuation corridor produces a fair range of ₹2,676.05 to ₹3,057.08, with base value near ₹2,828.61 (+17.1% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Below normalized range

Forward EPS

₹73.70

Forward P/E

32.8x

Base Fair Value

₹2,828.61

Fair Range

₹2,676.05 - ₹3,057.08

Upside To Base

+17.1%

Estimate Source

Live forward EPS

Growth Estimate

-31.0%

P/E

5Y Average

32.04

Current

54.06

Overvalued

41.48

Undervalued

36.31

EV/EBITDA

5Y Average

20.36

Current

34.34

Overvalued

24.97

Undervalued

13.50

P/S

5Y Average

5.53

Current

9.35

Overvalued

6.78

Undervalued

3.67

Peers & Comparison

Sector: Health Care · Theme: Pharmaceuticals

Pharmaceuticals Peers8 peers

Avg P/E: 46x

Company	Rev. Growth	Margin	P/E	vs Avg	52W Perf.
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals	+54.8%	13.9%	78.6x Premium	+71% vs avg	+34.9%
CIPLA LTD CIPLAPharmaceuticals	+3.5%	12.0%	35.0x Undervalued	-24% vs avg	-6.5%
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals	+23.1%	10.1%	36.4x Undervalued	-21% vs avg	+11.3%
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals	+6.5%	22.4%	37.8x Undervalued	-18% vs avg	-15.8%
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals	+24.8%	19.6%	39.8x Fair	-13% vs avg	+30.6%
LUPIN LIMITED LUPINPharmaceuticals	+32.0%	18.5%	18.7x Undervalued	-59% vs avg	+14.5%
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals	+29.1%	15.0%	91.4x Premium	+99% vs avg	+116.1%
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals	-5.6%	10.0%	30.4x Undervalued	-34% vs avg	-3.9%

WHY THESE PEERS

J B CHEMICALS AND PHARMA trades at a premium (54.2x vs peer avg 46.0x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include TORRENT PHARMACEUTICALS L, CIPLA LTD, GLENMARK PHARMACEUTICALS — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹836 CrMar 2026

Latest net profit

₹97 CrMar 2026

Latest EPS

₹6.01Mar 2026

Net margin

23.0%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %

Revenue
Net income
Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share

Revenue
EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore

Annual view

Debt
Free cash flow
Cash & equivalents

Results

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	699	853	837	800	809	952	956	914	901	1,040	1,023	991	836
Expenses +	538	618	602	585	614	679	688	668	670	747	724	721	642
Operating Profit	161	235	235	215	195	273	268	245	231	293	298	270	195
OPM %	23%	28%	28%	27%	24%	29%	28%	27%	26%	28%	29%	27%	23%
Other Income +	3	5	7	7	16	5	9	7	14	14	14	17	-17
Interest	12	11	9	12	8	4	2	2	1	1	1	2	1
Depreciation	31	31	32	33	40	40	41	41	44	41	43	44	49
Profit before tax	122	198	201	176	163	234	234	210	199	265	268	241	128
Tax %	27%	27%	28%	27%	23%	26%	26%	25%	25%	25%	25%	26%	25%
Net Profit +	89	145	145	128	126	173	173	156	150	198	200	179	97
EPS in Rs	5.73	9.34	9.36	8.25	8.11	11.16	11.15	10.06	9.62	12.68	12.80	11.44	6.01
Raw PDF
YOY Sales Growth %	19.80%	19.05%	13.08%	9.76%	15.74%	11.70%	14.22%	14.17%	11.39%	9.20%	7.00%	8.47%	-7.20%
Material Cost %	34.27%	33.95%	33.64%	32.58%	34.29%	33.88%	33.88%	33.08%	33.67%	31.83%	31.78%	31.36%	30.17%
Employee Cost %	17.71%	16.32%	16.90%	17.71%	17.69%	16.45%	16.79%	17.90%	18.43%	17.51%	17.31%	18.11%	21.99%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-27.18
Other income normal	3.30	5.13	6.84	6.61	16.10	5.16	8.89	7.16	13.53	13.90	14.25	16.89	10.24
Exceptional items AT	0	0	0	0	0	0	0	0	0	0	0	0	-19
Profit excl Excep	89	145	145	128	126	173	173	156	150	198	200	179	116
Profit for PE	89	145	145	128	126	173	173	156	150	198	200	179	116
Profit for EPS	89	145	145	128	126	173	173	156	150	198	200	179	97
YOY Profit Growth %	7%	43%	48%	26%	42%	20%	19%	22%	19%	14%	16%	15%	-23%

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

Holder	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters +	47.84%	47.73%	47.56%	47.55%	48.80%
FIIs +	18.30%	17.77%	15.31%	14.88%	16.33%
DIIs +	18.71%	19.62%	22.83%	23.35%	21.38%
Public +	15.13%	14.87%	14.31%	14.21%	13.48%
Others	0.02%	0.01%	—	0.01%	0.01%

Mar 2026

Promoters +

FIIs +

DIIs +

Public +

Others

Events Timeline

Annual Report FY26

FY2026PDFCompany Reports Open

Intimation Of Effective Date Of Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders

Jul 08, 2026PDFCompany Reports Open

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jul 07, 2026PDFCompany Reports Open

Record Date For The Purpose Of Determining The Shareholders Of The Company Who Shall Be Entitled To Receive Fully Paid-Up Equity Shares Of Torrent Pharma As Per The Share Exchange Ratio

Jul 07, 2026PDFCompany Reports Open

Receipt Of Certified Copy Of Order Passed By National Company Law Tribunal, Ahmedabad Bench ('NCLT') Regarding The Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders.

Jul 07, 2026PDFCompany Reports Open